Suven Life Scie.
Drug Manufacturers - Specialty & Generic · SUVEN
Small CapHealthcareDistressed / Turnaround
Venkateswarlu Jasti
Managing Director · Visionary
Company DNA
Founder-Centric
About
Suven Life Scie. is a Small Cap company in the Healthcare sector, listed on NSE as SUVEN. With a market cap of ₹3K Cr and revenue of ₹7 Cr, it is currently in the Distressed / Turnaround phase. Known for its Founder-Centric culture and Disruptor approach to innovation, the company operates at a Seasonal-Burst pace. Heavy reliance on promoter visionary leadership for navigating complex R&D and pharmaceutical business cycles. Its strategic mandate: Struggling with significant clinical research cash burn, the firm requires urgent financial stabilization and a strategic pivot in R&D focus.
FAQ
What kind of company is Suven Life Scie.?
Suven Life Scie. is a Small Cap Healthcare company (SUVEN) in the Distressed / Turnaround phase with a market cap of ₹3K Cr. It is classified as Founder-Centric in culture.
What is Suven Life Scie.'s culture and work environment like?
Suven Life Scie. has a Founder-Centric culture with Disruptor innovation DNA and a Seasonal-Burst pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Heavy reliance on promoter visionary leadership for navigating complex R&D and pharmaceutical business cycles.
Who leads Suven Life Scie.?
Suven Life Scie. is led by Venkateswarlu Jasti (Managing Director), a Visionary leader with 36 years of experience.
What are Suven Life Scie.'s financials?
Suven Life Scie. reported revenue of ₹7 Cr in FY25 with a 5-year revenue CAGR of -17.5%. Operating margin: -2572.9%. Market cap: ₹3K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationDisruptor
PaceSeasonal-Burst
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleDistressed / Turnaround
Heavy reliance on promoter visionary leadership for navigating complex R&D and pharmaceutical business cycles.
Mandate
Struggling with significant clinical research cash burn, the firm requires urgent financial stabilization and a strategic pivot in R&D focus.
Struggling with significant clinical research cash burn, the firm requires urgent financial stabilization and a strategic pivot in R&D focus.
Financials
Revenue FY25₹7 Cr
PAT FY25₹-1607450000
Rev CAGR 5Y-17.5%
OPM-2572.9%
NPM-2415.1%
ROE-146.1%
ROCE-153.3%
P/E—
Fwd P/E7.1
P/B10.9
D/E—
Mkt Cap₹3K Cr
Promoter59.4%
Institutional1.8%
Similar Culture
Could You Lead Suven Life Scie.?
Take the Genome Benchmark →